Prospective observational study of the long term hazards of biologic therapy in rheumatoid arthritis.

Trial Profile

Prospective observational study of the long term hazards of biologic therapy in rheumatoid arthritis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Tocilizumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms BSRBR-RA
  • Most Recent Events

    • 17 Jun 2017 Preliminary results (n= 417) presented at the 18th Annual Congress of the European League Against Rheumatism
    • 30 Aug 2013 Planned end date changed from 31 Dec 2014 to 30 Sep 2018 as reported by United Kingdom Clinical Research Network record .
    • 08 Aug 2013 Accrual to date is 73% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top